Regado had all of its eggs in one basket when it took its lead therapy into a Phase III trial on its own. And now that the anticoagulant study has been shelved after signs of a severe allergic reaction were seen among patients, the biotech is cutting more than half of its staffers in an effort to preserve cash and review what kind of moves it can still make.
Back at the beginning of this month, Seattle-based VentiRx spread the news that it had raised a venture round for its newly fast-tracked TLR8 cancer vaccine research, but didn't disclose just how much it had in hand. A new filing at the SEC, though, puts the venture figure at $50.6 million, with another $2.4 million or so left to add in the planned raise.
The U.S. drugmaker will build a new campus in New Jersey for about 2,500 that it promises will pump up "collaboration, creativity and innovation," much as Biogen Idec, Novartis and others have done before it.
Last week the FDA cracked down hard on low-T therapies. Its expert panel voted to advise the agency to restrict the use of such drugs for a specific medical need.
After two false starts in the summer, drug delivery company Microlin Bio is once again withdrawing its planned IPO due to unfavorable market conditions. It had hoped to raise $28 million by offering 5.1 million shares on the Nasdaq priced between $4.50 and $5.50, Renaissance Capital reports.
Lipocine is touting positive late-stage results for its testosterone replacement pill, gearing up for intense FDA scrutiny amid a sea change in how the regulator looks at so-called low-T treatments.
A Purdue University team has created a new chip that promises to help test how cancer-killing nanoparticles react in a tumor environment. Because different nanoparticles perform vastly different functions in drug delivery, it's important to determine early on what kind of effect they will have on a tumor and what it would take to improve their outcome.
Titan Pharmaceuticals said yesterday that the Phase III study of its Probuphine subdermal implant for the treatment of opioid dependence is now halfway to full enrollment and on track to conclude by mid-2015, giving the company a second crack at FDA approval.
As researchers and investors toast renewed optimism for a new generation of gene therapies, biotech bellwether Biogen Idec is deepening its commitment to the space, another sign of life for the resurgent field.
Lonely, depressed, stressed? There's a smartphone app that can read your mood like a book. At Dartmouth, student researchers developed and tested StudentLife, an app that can detect depression and stress levels.